<p>CreativeOne Wealth LLC 在第一季度根据其最近向美国证券交易委员会提交的 13F 表格，增加了对辉瑞公司（NYSE:PFE - 免费报告）股份的持有，增幅为 31.7%。该基金在此期间购买了额外的 42,949 股后，持有该生物制药公司 178,513 股股票。根据其最近向美国证券交易委员会的提交，CreativeOne Wealth LLC 在辉瑞的持股价值为 4,523,000 美元。</p>
<ul>
<li>3 只长期分红股票，价格低于 50 美元</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。贝斯默集团（Bessemer Group Inc.）在第一季度将其在辉瑞的持股增加了 11.1%。贝斯默集团目前持有 132,478 股辉瑞的股票，价值 3,358,000 美元，此前在此期间又收购了 13,228 股。Capital Advisors Inc. OK 在第一季度将其在辉瑞的持股增加了 1.2%。Capital Advisors Inc. OK 目前持有 1,413,472 股辉瑞的股票，价值 35,817,000 美元，此前在上个季度又收购了 17,032 股。丘吉尔管理公司（CHURCHILL MANAGEMENT Corp）在第一季度收购了辉瑞的新股份，价值 8,283,000 美元。阿尔塔顾问有限公司（Alta Advisers Ltd）在第一季度将其在辉瑞的持股增加了 69.6%。阿尔塔顾问有限公司目前持有 31,912 股辉瑞的股票，价值 809,000 美元，此前在上个季度又购买了 13,100 股。最后，WCM 投资管理公司（WCM Investment Management LLC）在第一季度将其在辉瑞的持股增加了 8.7%。WCM 投资管理公司目前持有 125,964 股辉瑞的股票，价值 3,176,000 美元，此前在上个季度又购买了 10,051 股。机构投资者持有该公司 68.36% 的股票。</p>
<h2>分析师评级上调和下调</h2>
<p>几家研究公司最近对 PFE 进行了评估。摩根士丹利（Morgan Stanley）在 8 月 6 日的研究报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 &#34;持平&#34; 的评级。汇丰银行（HSBC）在 5 月 19 日的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该公司给予 &#34;买入&#34; 的评级。瑞银集团（UBS Group）在 4 月 30 日的研究报告中将辉瑞的目标价从 24.00 美元上调至 25.00 美元，并给予该股票 &#34;中性&#34; 的评级。Leerink Partners 在 4 月 30 日的报告中将辉瑞的目标价从 28.00 美元下调至 26.00 美元，并对该股票给予 &#34;市场表现&#34; 的评级。最后，杰富瑞金融集团（Jefferies Financial Group）在 5 月 21 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 &#34;买入&#34; 的评级。两位研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 28.12 美元。</p>
<ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
<p><strong>阅读我们对 PFE 的最新分析</strong></p>
<h2>辉瑞股票上涨 0.6%</h2>
<p>周四，NYSE PFE 开盘价为 25.08 美元。该公司的债务与股本比率为 0.65，流动比率为 1.16，速动比率为 0.85。辉瑞公司的 1 年最低价为 20.92 美元，1 年最高价为 30.43 美元。该公司的 50 日移动平均线为 24.76 美元，200 日移动平均线为 24.40 美元。该股票的市值为 1425.7 亿美元，市盈率为 13.34，市盈增长比率为 0.89，贝塔值为 0.52。</p>
<ul>
<li>5 只被低估的高分红股票，具有强劲的派息潜力</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近于 8 月 5 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为 0.78 美元，超出市场共识预期的 0.58 美元，超出幅度为 0.20 美元。该公司本季度的收入为 146.5 亿美元，而分析师预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。该公司的收入同比增长 10.3%。去年同期，该公司每股收益为 0.60 美元。辉瑞已将其 2025 财年的指引设定为 2.900-3.100 EPS。卖方分析师预测辉瑞公司今年的每股收益将为 2.95 美元。</p>
<h2>辉瑞宣布分红</h2>
<p>该公司最近还披露了一项季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日（星期五）的股东将获得每股 0.43 美元的分红。该分红的除息日为 7 月 25 日（星期五）。这代表着年化分红为 1.72 美元，分红收益率为 6.9%。辉瑞的派息比率目前为 91.49%。</p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>经纪公司排名在股票选择中的重要性</li>
<li>亚马逊的图表刚刚闪现出三角形形态——该如何应对</li>
<li>投资 5G 技术的顶级股票</li>
<li>3 只分析师目前看好的被低估股票——你应该买吗？</li>
<li>什么是分红？购买最佳分红股票</li>
<li>Williams-Sonoma 第二季度业绩证明其买入持有的质量</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>CreativeOne Wealth LLC 在第一季度将其在辉瑞公司的持股增加了 31.7%，目前拥有 178,513 股，价值 450 万美元。其他机构投资者也增加了在辉瑞的持仓。分析师对该股票的评级意见不一，普遍评级为 “持有”，目标价为 28.12 美元。辉瑞公司报告了超出预期的每股收益为 0.78 美元，收入为 146.5 亿美元。该公司宣布季度股息为每股 0.43 美元，将于 9 月 2 日支付</p>

<p>CreativeOne Wealth LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 31.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 178,513 shares of the biopharmaceutical company's stock after purchasing an additional 42,949 shares during the period. CreativeOne Wealth LLC's holdings in Pfizer were worth $4,523,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>CreativeOne Wealth LLC 在第一季度根据其最近向美国证券交易委员会提交的 13F 表格，增加了对辉瑞公司（NYSE:PFE - 免费报告）股份的持有，增幅为 31.7%。该基金在此期间购买了额外的 42,949 股后，持有该生物制药公司 178,513 股股票。根据其最近向美国证券交易委员会的提交，CreativeOne Wealth LLC 在辉瑞的持股价值为 4,523,000 美元。</p>
</div><ul>
<li>3 Long-Term Dividend Buys You Can Get for Under $50</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只长期分红股票，价格低于 50 美元</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Bessemer Group Inc. increased its stake in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK boosted its holdings in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the 1st quarter valued at $8,283,000. Alta Advisers Ltd raised its position in Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC raised its position in Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after purchasing an additional 10,051 shares during the last quarter. Institutional investors own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。贝斯默集团（Bessemer Group Inc.）在第一季度将其在辉瑞的持股增加了 11.1%。贝斯默集团目前持有 132,478 股辉瑞的股票，价值 3,358,000 美元，此前在此期间又收购了 13,228 股。Capital Advisors Inc. OK 在第一季度将其在辉瑞的持股增加了 1.2%。Capital Advisors Inc. OK 目前持有 1,413,472 股辉瑞的股票，价值 35,817,000 美元，此前在上个季度又收购了 17,032 股。丘吉尔管理公司（CHURCHILL MANAGEMENT Corp）在第一季度收购了辉瑞的新股份，价值 8,283,000 美元。阿尔塔顾问有限公司（Alta Advisers Ltd）在第一季度将其在辉瑞的持股增加了 69.6%。阿尔塔顾问有限公司目前持有 31,912 股辉瑞的股票，价值 809,000 美元，此前在上个季度又购买了 13,100 股。最后，WCM 投资管理公司（WCM Investment Management LLC）在第一季度将其在辉瑞的持股增加了 8.7%。WCM 投资管理公司目前持有 125,964 股辉瑞的股票，价值 3,176,000 美元，此前在上个季度又购买了 10,051 股。机构投资者持有该公司 68.36% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several research firms have recently weighed in on PFE. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, August 6th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, May 19th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, April 30th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a &#34;market perform&#34; rating on the stock in a report on Wednesday, April 30th. Finally, Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $28.12.</p>
<div class="lb-trans"><p>几家研究公司最近对 PFE 进行了评估。摩根士丹利（Morgan Stanley）在 8 月 6 日的研究报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 &#34;持平&#34; 的评级。汇丰银行（HSBC）在 5 月 19 日的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该公司给予 &#34;买入&#34; 的评级。瑞银集团（UBS Group）在 4 月 30 日的研究报告中将辉瑞的目标价从 24.00 美元上调至 25.00 美元，并给予该股票 &#34;中性&#34; 的评级。Leerink Partners 在 4 月 30 日的报告中将辉瑞的目标价从 28.00 美元下调至 26.00 美元，并对该股票给予 &#34;市场表现&#34; 的评级。最后，杰富瑞金融集团（Jefferies Financial Group）在 5 月 21 日的报告中将辉瑞的目标价从 32.00 美元上调至 33.00 美元，并给予该股票 &#34;买入&#34; 的评级。两位研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，共识目标价为 28.12 美元。</p>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
</div><p><strong>Read Our Latest Analysis on PFE</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 PFE 的最新分析</strong></p>
</div><h2>Pfizer Stock Up 0.6%</h2>
<div class="lb-trans"><h2>辉瑞股票上涨 0.6%</h2>
</div><p>NYSE PFE opened at $25.08 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business's 50-day moving average is $24.76 and its 200 day moving average is $24.40. The stock has a market capitalization of $142.57 billion, a PE ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52.</p>
<div class="lb-trans"><p>周四，NYSE PFE 开盘价为 25.08 美元。该公司的债务与股本比率为 0.65，流动比率为 1.16，速动比率为 0.85。辉瑞公司的 1 年最低价为 20.92 美元，1 年最高价为 30.43 美元。该公司的 50 日移动平均线为 24.76 美元，200 日移动平均线为 24.40 美元。该股票的市值为 1425.7 亿美元，市盈率为 13.34，市盈增长比率为 0.89，贝塔值为 0.52。</p>
</div><ul>
<li>Top 5 Undervalued Dividend Stocks With Strong Payout Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只被低估的高分红股票，具有强劲的派息潜力</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近于 8 月 5 日发布了其财报。这家生物制药公司报告本季度每股收益（EPS）为 0.78 美元，超出市场共识预期的 0.58 美元，超出幅度为 0.20 美元。该公司本季度的收入为 146.5 亿美元，而分析师预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。该公司的收入同比增长 10.3%。去年同期，该公司每股收益为 0.60 美元。辉瑞已将其 2025 财年的指引设定为 2.900-3.100 EPS。卖方分析师预测辉瑞公司今年的每股收益将为 2.95 美元。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer's payout ratio is presently 91.49%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日（星期五）的股东将获得每股 0.43 美元的分红。该分红的除息日为 7 月 25 日（星期五）。这代表着年化分红为 1.72 美元，分红收益率为 6.9%。辉瑞的派息比率目前为 91.49%。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to Do</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>3 Undervalued Stocks Analysts Are Loving Right Now—Should You?</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>经纪公司排名在股票选择中的重要性</li>
<li>亚马逊的图表刚刚闪现出三角形形态——该如何应对</li>
<li>投资 5G 技术的顶级股票</li>
<li>3 只分析师目前看好的被低估股票——你应该买吗？</li>
<li>什么是分红？购买最佳分红股票</li>
<li>Williams-Sonoma 第二季度业绩证明其买入持有的质量</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CreativeOne Wealth LLC Has $4.52 Million Position in Pfizer Inc. $PFE

- CreativeOne Wealth LLC 在第一季度增持 Pfizer 股份 31.7%，持股 178,513 股。  
- Pfizer 第一季度每股收益为 0.78 美元，超出预期，营收 146.5 亿美元。  
- Pfizer 宣布季度股息 0.43 美元，年化股息收益率为 6.9%。  

CreativeOne Wealth LLC 在辉瑞公司拥有价值 452 万美元的持仓